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Selection for b2-microglobulin mutation in mismatch repair-
defective colorectal carcinomas
David C. Bicknell*, Loukas Kaklamanis†, Richard Hampson‡, Walter F. Bodmer*
and Peter Karran‡
Novel peptide antigens complexed with human
leukocyte antigen (HLA) and b2-microglobulin (b2M)
molecules are presented at the cell surface to cytotoxic
T lymphocytes (CTLs), provoking lysis of the antigen-
presenting cell [1]. In tumour cells, genetically altered
or abnormally expressed proteins provide a source of
peptides that can be presented to CTLs; the resulting
anti-tumour CTL responses may provide part of the
body’s defence against cancer. Disabling mutations in
the HLA and b2M proteins required for peptide
presentation allow a tumour cell to escape destruction
by CTLs. Cells with deficient DNA mismatch repair have
high spontaneous mutation rates [2] and produce many
altered proteins that are a potential source of
numerous unique peptides. Mutator tumour cells might
therefore be particularly vulnerable to immune
surveillance and CTL attack. Mutator phenotypes [3,4]
and loss of b2M (or HLA) expression [5,6] are both
relatively common among sporadic colorectal tumours.
We have compared the frequency of b2M mutations in
sporadic colorectal and other tumours with and without
a mutator phenotype. Mutations were more frequent
among colorectal tumours with the microsatellite
instability indicative of a defect in DNA mismatch
repair. The inactivating b2M mutations were
predominantly frameshifts, which is consistent with the
underlying mismatch repair defects. Evasion of immune
surveillance by acquiring b2M mutations therefore
occurs at high frequency in tumour cells with a mutator
phenotype due to defective DNA mismatch repair.
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Results and discussion
Single-stranded conformation polymorphism (SSCP) was
used to analyze the b2M gene in an initial series of 280
tumour samples. Table 1 presents the types of tumour and
the frequency of b2M mutations. Nine b2M mutations
were detected among 147 colorectal tumour biopsies. In
contrast, only one of 133 non-colorectal tumours was
found to contain a b2M mutation. Thus, among the
tumours we analyzed, b2M mutations were significantly
(p < 0.02) overrepresented in the colorectal carcinomas.
The b2M mutations were identified by isolating and
sequencing the PCR products (Table 2). In the colorectal
carcinomas, six mutations were in the sequence encoding
the leader peptide of b2M, two were located in exon 2 and
one tumour (C43) contained a point mutation in the base
immediately preceding the ATG initiation codon. The
mutation in the only non-colorectal tumour, a lymphoma,
was localized to exon 1 but was not further identified.
Five of the b2M mutations in the colorectal tumours were
frameshifts at repeated elements. Overrepresented among
these (three of nine) were 2 base-pair (bp) deletions in an
8 bp (CT)4 repeat in the sequence encoding the leader
peptide. A similar mutation is found at high frequency in
some colorectal-carcinoma-derived cell lines [7,8].
Tumour StM78 contained a minus (TG) frameshift at a
(TG)2 repeat in the leader peptide sequence. The muta-
tion in exon 2 of StM185 was also in a repeated region; in
this case, the mutation was a frameshift resulting from loss
of an A from (A)5. These mutations introduce a termina-
tion signal 46 and 34 codons downstream, respectively. 
In all DNA samples, both the wild-type and mutated b2M
alleles were present. This may indicate heterozygosity for
b2M mutations or might reflect contamination with normal
tissue. Seven of the nine mutated tumours were examined
Table 1
b2M mutations in tumours of different sites
Tumour Number analyzed Number with b2M mutations
Colorectal 147 9
Melanoma 30 0
Breast 48 0
Ovary 21 0
Lymphoma 34 1
Total 280 10
PCR (polymerase chain reaction) and SSCP analysis of the b2M gene
was performed as described previously using primers derived from the
intronic sequences [7].
by immunocytochemistry with antibodies W6/32 (directed
against the b2M–HLA A,B,C complex) and BBM.1
(directed against b2M). In all cases, the expression of b2M
was reduced in comparison to that in adjacent normal
stromal cells and lymphocytes. In three cases, b2M expres-
sion was undetectable (Table 2), suggesting that these
tumours were not heterozygous for the b2M mutations.
Contaminating DNA from normal tissue surrounding the
tumour, or from regions of tumour with normal b2M, are
the obvious source of wild-type DNA in the tumour
samples that lacked detectable b2M.
Microsatellite instability can be used to detect defects in
DNA mismatch repair. DNA from 71 colorectal tumours
was analyzed at three or more CA repeat microsatellite
markers. For 37 of these samples, DNA from adjacent
uninvolved epithelium was analyzed in parallel. Seven of
the 71 tumour DNA samples (10 %) showed evidence of
alterations at two or more microsatellite loci and were
considered to exhibit microsatellite instability. No insta-
bility was detected among the normal DNA samples
(< 3 %). These observations are in agreement with pub-
lished values of around 10–15 % for the frequency of
microsatellite instability in sporadic colorectal carcinomas
[9] and indicate that our panel of colorectal carcinomas is
representative in this respect. Instability was observed in
five of nine samples with b2M mutations. These included
tumours that were homozygous or hemizygous for b2M
loss, as well as apparent heterozygotes in which b2M
expression was considerably reduced (Table 2). Mismatch
repair defects are therefore significantly more common
amongst tumours with b2M mutations (5/9) than in col-
orectal carcinomas in general (p < 0.01). These data are in
agreement with our preliminary observations that b2M
mutations are more common in mismatch-repair-defective
colorectal cell lines [8]. Microsatellite instability is found
infrequently in the tumour types that made up most of
the non-colon carcinomas in our study — breast ([10] and
R. Tan, P.K. and A.L. Harris, data not shown) and
melanoma [11]. This is consistent with our finding of a
lower frequency of b2M mutations among these tumours
than in the colorectal carcinomas.
An increased mutation rate alone is unlikely to account for
the observed frequency of b2M mutations in mismatch
repair-defective colorectal tumours. Four tumors with
b2M mutations did not exhibit microsatellite instability
(Table 2). The high frequency of b2M mutations among
tumours with a normal spontaneous mutation rate implies
that a second factor contributes to the emergence of
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Table 2
Mutation and expression of b2M in colorectal tumours
Tumour Location Mutation Site Expression* Microsatellite locus†
C43 Base before ATG G→A point mutation (GA)2 (upstream of ATG) Low Stable
StM78 Leader sequence TG deletion (TG)2 (bases 24–27‡) Not examined Stable
3624/91 Leader sequence C→G point mutation (CG)2 (bases 30–33‡) Not detectable Stable
C14 Leader sequence CT deletion (CT)4 (bases 37–44‡) Low Stable
C108 Leader sequence CT deletion (CT)4 (bases 37–44‡) Low Unstable
13971/92 Leader sequence CT deletion (CT)4 (bases 37–44‡) Not detectable Unstable
3822/93 Leader sequence CT→GG Non-repetitive sequence Not detectable Unstable
C84T Exon 2 G→A point mutation Non-repetitive sequence Low Unstable
StM185 Exon 2 A deletion (A)5 (codons 47/48§) Not examined Unstable
*Immunocytochemical detection of b2M was performed with the
monoclonal antibodies W6/32, which recognizes assembled class I
major histocompatability complex molecules [1], and BBM.1, which is
specific for b2M [18]. Staining was performed using alkaline
phosphatase as previously described [19]. Frozen tissue sections
(5 mm thick) were fixed in cold acetone for 10 min at room temperature
and air-dried overnight. Primary antibody was added to the dry sections
in a humidified chamber for 30 min. Anti-mouse immunoglobin G
(DAKO Z259) and APAAP complex (DAKO D651), both diluted 1:50 in
Tris-buffered saline (TBS), were added sequentially (separated by a
TBS washing period of 5 min). Incubation with the sections was for 30
min in each case. These steps were repeated to enhance the intensity
of the final staining. After washing with TBS, the alkaline phosphatase
substrate was then added for 15 min. Sections were counterstained
with haematoxylin and mounted in an aqueous mounting medium.
Tumour cell expression was determined by comparing the intensity of
staining to that of lymphocytes and surrounding stromal cells. †Four loci
containing dinucleotide repeat sequences on different chromosomes
were analyzed. These loci were D2S123 (chromosome 2), D10S209
and AFMb001 (chromosome 10) and D17S941 (chromosome 17). In
some cases, instability was confirmed by further analysis of the
D13S175, D2S378, D2S119, D10S197 and D17S941 loci. Primer
sequences have been published elsewhere [20] and were used in
standard PCR reactions containing 50 mM KCl, 10 mM Tris–HCl
(pH 8.3), 1.5 mM MgCl2, 0.25 % NP40, 200 mM NTPs, 0.2 mM of the
appropriate primer combination (the 5′ primer was labelled with a
fluorescent tag), 1 unit Taq polymerase and 0.5–1 mg genomic DNA.
Amplification was performed with 35 cycles of 90 °C (1 min), 54 °C
(30 sec) and 72 °C (30 sec). PCR products were analyzed on an
Applied Biosystems ABI 337A DNA Genotyper. Samples with variability
at two or more loci were classified as unstable. ‡Numbers represent
base position in leader sequence. §Codon number.
tumours with b2M mutations. In all cases we examined, the
mutation was associated with a significant reduction in b2M
expression. The selective advantage gained by the conse-
quent loss of ability to present HLA-associated antigen is
therefore the most likely contributary factor. The high fre-
quency with which acquired resistance to immunotherapy
by CD8+ T cells is associated with loss of b2M expression in
melanoma [12] is evidence of the selective power of the
immune system. Defects in mismatch repair would there-
fore be expected to influence the emergence of b2M-defec-
tive tumours in two ways. First, repair-defective cells
accumulate frameshift mutations in expressed genes [13,14]
and consequently synthesize many altered peptides. More
vigorous CTL responses against repair-deficient tumours
might thereby provide a heightened selective pressure for
loss, or reduction, of surface antigen presentation [15].
Second, the reiterated sequences in the b2M gene repre-
sent ‘hotspots’ for inactivating frameshifts in a repair-defi-
cient background. These two factors provide a ready
explanation for the preponderance of b2M mutations in
tumour cells defective in mismatch repair.
An independent example of the overrepresentation of a
particular mutation — as a consequence of a mutator phe-
notype combined with a selective pressure — is provided
by the loss of responsiveness of colorectal carcinomas to
transforming growth factor-b (TGF-b) [16]. Frameshifts in
repeated sequences within the TGF-b receptor type II
gene are frequently associated with inactivation of the
TGF-b receptor in colon tumours with microsatellite insta-
bility. Endometrial tumours are not normally responsive to
TGF-b, and TGF-b receptor mutations are not found in
endometrial tumours with microsatellite instability [17].
Thus, the acquisition of a mutation in an identifiable
hotspot and selective pressure are both required for the
emergence of tumours with the altered genotype.
Loss of b2M expression has profound effects on peptide
presentation because b2M is required for antigen presenta-
tion by all class I HLA molecules (HLA-A, HLA-B and
HLA-C). Our data indicate that loss or reduction of b2M
expression can arise through mutation in the b2M gene, and
that this event is particularly likely in colorectal tumours
with defects in mismatch repair. This, together with the
increased susceptibility of such repair-defective cells to
elimination by CTLs, provides a mechanistic explanation
for the association between microsatellite instability and
b2M gene mutations in colorectal tumours.
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